The aim of this study is to evaluate neoadjuvant VSV-IFNβ-NIS therapy for osteosarcoma using a comparative oncology approach and characterize anti-tumor immune responses in spontaneous canine osteosarcoma. This evidence concerns the gene IFNB1 and neoplasm.